[ad_1]
The results of the initial analysis of the COVE study evaluating the efficacy of the Moderna vaccine are published in The New England Journal of Medicine.
This is reported by Medical Thispress with reference to Brigham and Women’s Hospital, where the tests were performed.
The findings suggest that the vaccine can prevent symptomatic infection.
Among the more than 30,000 participants randomized to receive the vaccine or placebo, 11 in the vaccine group developed symptomatic COVID-19 compared to 185 participants who received placebo, showing an efficacy of 94.1% in the prevention of symptomatic coronavirus infection.
Cases of severe COVID-19 were seen only in volunteers who received placebo.
The response to immunization was moderate: about half of the recipients experienced fatigue, muscle pain, joint pain, and headache, especially after the second dose. In most cases, these effects started about 15 hours after vaccination and disappeared after two days without consequences.
MedOboz previously reported that eight nursing home workers in Germany accidentally received a five times higher dose of the coronavirus vaccine.
Haven’t you subscribed to our Telegram yet? Press fast!
